NEW DELHI/HYDERABAD: India's generic companies are likely to continue in business-as-usual mode as US President Donald Trump's 100% levy on pharmaceuticals is targeted at branded and patented medicines, but it may also prompt some of them to rethink their playbook. Industry experts told TOI that the country's largest drugmaker Sun Pharma could face headwinds as its drug sales in US totalled $1.1 billion in FY25 (in which patented drugs have a significant portion), which was around 17% of its total revenue. Analysts added that branded biosimilars manufactured by companies, including Biocon, may be affected. Companies with manufacturing bases in US - including Sun Pharma, Dr Reddy's and Cipla - could cushion the blow by shifting production of higher-value specialty and niche drugs from I

See Full Page